Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes

D. Dowlatshahi, A. M. Demchuk, M. L. Flaherty, Myzoon Ali, P. L. Lyden, E.E. Smith

    Research output: Contribution to journalArticle

    Abstract

    Hematoma expansion (HE) is a surrogate marker in intracerebral hemorrhage (ICH) trials. However, the amount of HE necessary to produce poor outcomes in an individual is unclear; there is no agreement on a clinically meaningful definition of HE. We compared commonly used definitions of HE in their ability to predict poor outcome as defined by various cutpoints on the modified Rankin Scale (mRS). In this cohort study, we analyzed 531 patients with ICH from the Virtual International Stroke Trials Archive. Primary outcome was mRS at 90 days, dichotomized into 0–3 vs 4–6. Secondary outcomes included other mRS cutpoints and mRS “shift analysis.” Sensitivity, specificity, and predictive values for commonly used HE definitions were calculated.

    Original languageEnglish
    Pages (from-to)1238-1244
    Number of pages7
    JournalNeurology
    Volume76
    Issue number14
    DOIs
    Publication statusPublished - 1 Apr 2011

    Keywords

    • hematoma
    • stroke
    • intracerebral hemorrhage

    Fingerprint Dive into the research topics of 'Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes'. Together they form a unique fingerprint.

  • Cite this

    Dowlatshahi, D., Demchuk, A. M., Flaherty, M. L., Ali, M., Lyden, P. L., & Smith, E. E. (2011). Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. Neurology, 76(14), 1238-1244. https://doi.org/10.1212/WNL.0b013e3182143317